Electrocore ECOR 深 沪
等待开盘 07-15 09:30:00 美东时间
6.15
-0.370
-5.67%
华盛通- 最 高6.75
- 今 开6.54
- 成交量 8.31万股
- 最 低 6.00
- 昨 收 6.52
- 总市值 5101.86万
- 52周最高 10.495
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 4.16
- 委 比 31.62%
- 总股本 829.57万
- 历史最高 303.75
- 量 比 0.60
- 振 幅 11.50%
- 历史最低 2.925
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多electroCore to present at iAccess Alpha Virtual Best Ideas Summer Investment Conference
electroCore to present at iAccess Alpha Virtual Best Ideas Summer Investment Conference Tullis Health Investors highlighted electroCore’s participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. Interim President and CFO Joshua Lev is scheduled to prese
06-17 20:48
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
electroCore, Inc. will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. Joshua Lev, Interim President and CFO, will present and host investor meetings. The company, specializing in non-invasive bioelectronic technologies for treating chronic pain and promoting wellness, will discuss its products including gammaCore® and Quell®. More details and registration available at the conference website.
06-17 12:00
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
06-15 17:11
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
electroCore, Inc. announced that a review article titled "Without getting under your skin: non-invasive stimulation activates the vagus nerve" has been accepted for publication in *Frontiers in Neuroscience*. Authored by a team of researchers, the article synthesizes decades of evidence supporting the effectiveness of cervical non-invasive vagus nerve stimulation (nVNS) in activating vagal pathways without surgical implantation. The review evalua...
06-09 12:00
electroCore director Thomas J. Errico acquires $59,790 of common shares
electroCore director Thomas J. Errico acquires $59,790 of common shares electroCore director Thomas J. Errico reported acquiring 10,000 common shares in two open-market buys at USD 5.98 to USD 5.99. His direct beneficial ownership rose to 360,071 common shares. Disclaimer: This news brief was create
05-26 20:52
electroCore to present at LD Micro Invitational XVI Conference
electroCore to present at LD Micro Invitational XVI Conference electroCore will present at LD Micro Invitational XVI Conference on May 18, 2026, at Luxe Sunset Boulevard Hotel in Los Angeles. Presentation scheduled for 10:30 a.m. PT, with one-on-one investor meetings planned through day. Disclaimer:
05-09 08:00
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. will participate in the LD Micro Invitational XVI Conference on May 18, 2026, in Los Angeles. Joshua Lev, Interim President and CFO, will present and host meetings. The company focuses on non-invasive bioelectronic technologies for health and wellness, offering products like gammaCore® and Quell®. More details available at www.electrocore.com.
05-09 00:00
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
electroCore Q1 EPS $(0.59) Misses $(0.51) Estimate, Sales $9.584M Beat $9.012M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 25.53 percent decrease over losses of $(0.47) per share from the
05-07 04:28
electroCore Announces First Quarter 2026 Financial Results
ElectroCore, Inc. reported Q1 2026 net sales of $9.6 million, a 43% year-over-year increase, driven by growth in VA prescription sales and Truvaga direct-to-consumer sales. The company also saw a 24% improvement in adjusted EBITDA loss to $2.3 million. Key highlights include VA prescription gammaCore revenue up 26%, Quell product line sales surpassing $1.0 million quarterly revenue, and Truvaga revenue growing 38% with improved marketing efficien...
05-06 20:05
